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ABSTRACT
Objective: To examine moderators and predictors of response to behavior therapy for tics in chil-
dren and adults with Tourette syndrome and chronic tic disorders.
Methods: Data from 2 10-week, multisite studies (1 in children and 1 in adults; total n 5 248)
comparing comprehensive behavioral intervention for tics (CBIT) to psychoeducation and sup-
portive therapy (PST) were combined for moderator analyses. Participants (177 male, 71 female)
had a mean age of 21.5 6 13.9 years (range 9–69). Demographic and clinical characteristics,
baseline tic-suppressing medication, and co-occurring psychiatric disorders were tested as
potential moderators for CBIT vs PST or predictors of outcome regardless of treatment assign-
ment. Main outcomes measures were the Yale Global Tic Severity Scale Total Tic score and the
Clinical Global Impression–Improvement score assessed by masked evaluators.
Results: The presence of tic medication significantly moderated response to CBIT vs PST (p 5
0.01). Participants showed tic reduction after CBIT regardless of tic medication status, but only
participants receiving tic medication showed reduction of tics after PST. Co-occurring psychiatric
disorders, age, sex, family functioning, tic characteristics, and treatment expectancy did not
moderate response. Across both treatments, greater tic severity (p 5 0.005) and positive par-
ticipant expectancy (p 5 0.01) predicted greater tic improvement. Anxiety disorders (p 5 0.042)
and premonitory urge severity (p 5 0.005) predicted lower tic reduction.
Conclusions: Presence of co-occurring attention-deficit/hyperactivity disorder, obsessive-
compulsive disorder, or anxiety disorders did not moderate response to CBIT. Although partici-
pants on tic medication showed improvement after CBIT, the difference between CBIT and
PST was greater for participants who were not on tic-suppressing medication.
ClinicalTrials.gov identifiers: The child and adult CBIT studies are listed on clinical trials.gov
(NCT00218777 and NCT00231985, respectively).
Classification of evidence: This study provides Class I evidence that CBIT is effective in reducing
tic severity across subgroups of patients with chronic tic disorders, although the difference
between treatments was smaller for participants on tic-suppressing medications, suggesting
reduced efficacy in this subgroup. Neurology® 2017;88:1029–1036
GLOSSARY
ADHD 5 attention-deficit/hyperactivity disorder; ADHD-RS 5 Attention Deficit Hyperactivity Disorder Rating Scale;
BFAM 5 Brief Family Assessment Measure III; CBIT 5 Comprehensive Behavioral Intervention for Tics; CGI-I 5 Clinical
Global Impression–Improvement; CGI-S 5 Clinical Global Impression–Severity; CTD 5 chronic tic disorder; LSM 5 least
squares means; OCD 5 obsessive-compulsive disorder; PST 5 psychoeducation and supportive therapy; TS 5 Tourette
syndrome; YGTSS 5 Yale Global Tic Severity Scale.
Chronic tic disorders (CTDs)—Tourette syndrome (TS) and chronic motor or vocal tic
disorder—are characterized by childhood onset of motor or vocal tics affecting an estimated
14/1,000 children.1 Tics usually begin between 5 and 7 years of age and reach peak severity
between 9 and 12 years, with gradual improvement through adolescence; a minority of
patients have moderate to severe tics into adulthood.2 CTDs often co-occur with other
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psychiatric disorders, including attention-
deficit/hyperactivity disorder (ADHD),
obsessive-compulsive disorder (OCD), and
other anxiety and mood disorders.3–5
Available treatments for CTDs focus on tic
reduction or a co-occurring condition.
Medications to reduce tic severity include
dopamine receptor blocking agents (e.g., hal-
operidol and risperidone) and a2-adrenergic
agonists (e.g., clonidine and guanfacine).6,7
Efficacy of Comprehensive Behavioral Inter-
vention for Tics (CBIT)8 for reducing tic
severity was demonstrated in 2 large,
10-week randomized controlled trials of
youth (n 5 126)9 and adults (n 5 122).10
In both trials, CBIT was compared to psy-
choeducation and supportive therapy (PST).
Given that the CBIT studies used the same
design and outcome measures, we combined
these datasets to identify baseline character-
istics that differentially affected response
to CBIT vs PST (moderators) or affected
outcome equally across both treatments
(predictors).11
METHODS Primary research question. The primary
research question was to examine moderators and predictors of
response to behavior therapy for tics in children and adults with
CTDs. This study provides Class I evidence.
Design. Participants were randomized (1:1) to CBIT or PST.
The random assignment was within-site and stratified by the
presence of tic medication.
Participants. Children, adolescents, and adults with diagnosis
of TS or CTD with a Clinical Global Impression of Severity
(CGI-S)12 score of moderate (4) or greater were eligible to
participate. Those with TS were required to have a Yale Global
Tic Severity Scale (YGTSS)13 Total Tic score of $13 in the
child study and $14 in the adult study. For participants with
CTD only, the YGTSS total motor or vocal tic scores had to be
$9 and $10 in the child and adult studies, respectively. Par-
ticipants on psychotropic medication (including tic medica-
tion) were eligible if the medication was stable for at least 6
weeks before baseline with no planned changes during the 10-
week trial. Individuals with IQ ,80, current diagnosis of
substance abuse or substance dependence, lifetime diagnosis
of autism spectrum disorder or psychotic disorder, or
previous treatment with 4 or more sessions of habit reversal
training for tics were excluded. Those with co-occurring
diagnoses (e.g., depression, anxiety, OCD, or ADHD) were
eligible if the condition did not require immediate treatment
or change in existing treatment.9,10
Three sites enrolled participants in the child study (Johns
Hopkins University, University of California at Los Angeles, Uni-
versity of Wisconsin–Milwaukee) and 3 sites enrolled older
adolescent and adult participants (Massachusetts General Hos-
pital/Harvard Medical School, Health Sciences Center University
of Texas at San Antonio, Yale University).
Table 1 Demographic and clinical characteristics of participants in CBIT trials
by treatment group (n 5 248)
CBIT
(n 5 124)
PST
(n 5 124)
Mean age, y (SD) 21.8 (13.9) 21.2 (13.9)
Study site, n (%)
Johns Hopkins University 20 (16.1) 21 (16.9)
University of California, Los Angeles 21 (16.9) 24 (19.4)
University of Wisconsin–Milwaukee 20 (16.1) 20 (16.1)
Massachusetts General Hospital 24 (19.4) 23 (18.5)
University of Texas Health
Science Center
21 (16.9) 19 (15.3)
Yale University 18 (14.5) 17 (13.7)
Sex
Male 84 (67.7) 93 (75.0)
Female 40 (32.3) 31 (25.0)
Race
White, non-Hispanic 99 (79.8) 106 (85.5)
White, Hispanic 17 (13.7) 9 (7.3)
Black 1 (0.8) 4 (3.2)
Asian/Pacific Islander 6 (4.8) 3 (2.4)
Other 1 (0.8) 2 (1.6)
Mean IQ (SD) 108.3 (13.0) 108.2 (13.6)
Diagnoses
Tourette syndrome 111 (89.5) 110 (88.7)
Chronic motor tic disorder 11 (8.9) 14 (11.3)
Chronic vocal tic disorder 2 (1.6) 0
Co-occurring diagnoses
No co-occurring disorders 45 (35.7) 51 (41.8)
Attention-deficit/hyperactivity
disorder
37 (29.8) 30 (24.2)
Obsessive-compulsive disorder 21 (16.9) 25 (20.2)
Anxiety disordera 35 (28.2) 38 (30.6)
Otherb 24 (19.4) 23 (18.5)
Medication status
No medication 84 (67.7) 87 (70.2)
On tic medication 40 (32.3) 37 (29.8)
Antipsychoticc 13 (10.5) 9 (7.3)
a-Agonistd 17 (13.7) 18 (14.5)
Anticonvulsante 1 (0.8) 3 (2.4)
Benzodiazepinef 2 (1.6) 1 (0.8)
a-Agonist and antipsychotic 5 (4.0) 2 (1.6)
Antipsychotic and
anticonvulsant
1 (0.8) 1 (0.8)
a-Agonist and anticonvulsant 0 1 (0.8)
Antipsychotic and
benzodiazepine
0 1 (0.8)
Continued
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Standard protocol approvals, registrations, and patient
consents. The studies were approved by the institutional review
boards at each site. Adult participants and parents of child partic-
ipants provided consent; children provided assent.
The child and adult CBIT studies are listed on clinical trials.
gov (NCT00218777 and NCT00231985, respectively).
Treatments. CBIT and PST consisted of 8 individually deliv-
ered 60- to 90-minute sessions administered over 10 weeks.
Caretakers of children and significant others of adults were
invited to participate. CBIT provides education about tic
disorders and relaxation training and teaches patients to inhibit
tics with a competing motor movement. CBIT also addresses
situational antecedents and consequences of tics as contextual
factors that may inadvertently occasion or reinforce tics. PST
provided developmentally relevant information about CTDs
and controlled for time and therapist attention, but did not
include tic management strategies. Therapists with at least
a master’s degree were trained to reliability on both treatments
and received weekly supervision at each site. Sessions were
recorded on video and a 13%–16% randomly selected set of
therapy sessions was independently reviewed for fidelity.9,10
Procedures. Developmentally appropriate structured diagnostic
interviews assessed for psychiatric diagnoses. The Anxiety Disor-
ders Interview Schedule for DSM-IV: Child Version14
supplemented with a tic disorders module was administered
separately to parents and youths in the child study. The
Structured Clinical Interview for DSM-IV15 with tic disorder
and adult ADHD modules was used in the adult trial.
Symptom severity of ADHD was assessed with parent ratings
and self-reports of the Attention Deficit Hyperactivity Disorder
Rating Scale (ADHD-RS).16 Full-scale IQ was assessed by the
Wechsler Abbreviated Scale of Intelligence17 in children and by
the Wechsler Test of Adult Reading18 in adults. An experienced
clinician at each site confirmed the presence and stability of tic
medication.
Outcome measures. The YGTSS13 is a semi-structured
interview that measures tic severity over the prior week. Motor
and phonic tics are separately rated on a 0–5 scale for number,
frequency, intensity, complexity, and interference. The YGTSS
Total Tic score was the first primary outcome measure. The
second primary outcome measure was the Clinical Global
Impression–Improvement (CGI-I)12 with scores ranging from
very much improved (1) to very much worse (7); scores of much
improved (1) or very much improved (2) defined positive
response. Trained raters, who were blind to treatment
assignment, administered the YGTSS and CGI-I at baseline,
midpoint (week 5), and endpoint (week 10).
Moderator and predictor variables. We selected baseline
characteristics as moderators that could influence differential
response to CBIT vs PST based on studies of behavioral interven-
tions for other neurodevelopmental disorders19–21 and on consen-
sus of CBIT investigators. The same variables were examined as
predictors, which are characteristics affecting response regardless
of treatment assignment.22 Selected variables included presence of
baseline tic medication, tic phenomenology (age at onset, current
severity, complexity, and premonitory urges), age, sex, family
functioning, treatment expectancy, and co-occurring ADHD,
OCD, and anxiety disorders.
Tic medication. Seventy-seven (31%) participants reported
taking 1 or more tic medications: 32 antipsychotics, 44 a2 ago-
nists, 5 mood stabilizers, and 4 benzodiazepines. Tic medication
status was initially coded 0 (on a medication) or 1 (no tic medi-
cation). To test the effects of the most common tic medications in
this sample, we created a 4-level variable: 1 5 no tic medications,
2 5 antipsychotics only, 3 5 a2 agonists only, and 4 5 both.
Tic phenomenology. We considered age at onset, tic com-
plexity (cutoff greater than 3 on the YGTSS complexity item),23
overall severity (CGI-S of moderate vs marked or greater), and
premonitory urge based on the 9-item self-report Premonitory
Urges for Tics Scale.24
Demographic and family characteristics. Age was examined
as a continuous variable. In addition, we dichotomized age into
9–15 years and $16 years. This division reflects the replicated
observation that tics tend to decline throughout adolescence.
Thus, study participants age 16 years and older may have a more
persistent form of CTDs. Family functioning was measured by
the Brief Family Assessment Measure III (BFAM),25 which re-
flects family communication, problem-solving, and affective
expression. The BFAM was completed by caregivers and partic-
ipants in the child study and by adult participants. A z score was
created based on the average of child and parent BFAM scores
and the raw scores from adult participants.
Treatment expectations. After the first CBIT or PST session,
we collected a 3-item questionnaire from participants, parents, and
therapists in the child study and from participants and therapists in
the adult study. Items such as “I expect to get control over my tics
though this treatment” were rated on a scale from 1 5 strongly
disagree to 5 5 strongly agree. Thus, higher scores indicated
greater expectancy for treatment benefits. z Scores were derived
from the average of child and parent ratings in the child study and
self-reports in the adult study and then merged.We also created a z
score for therapist treatment expectation across both trials.
Data analysis. The effect of treatment on the YGTSS Total
Tic score was tested with mixed-model repeated-measures
analyses, adjusted for baseline scores.26 These analyses were
conducted on the modified intention-to-treat population (all
participants with at least 1 postrandomization assessment visit
[n 5 232]). The model included fixed effects for treatment (2
levels), time (5 and 10 weeks), site (6 sites), interaction of
treatment with time, a random effect for participant, and 3-
and 2-way interactions of time, treatment, and moderator
variable. Treatment-by-site interactions were not significant
for any of the outcome variables and were excluded from the
models. Three-way interactions (treatment 3 time 3
moderator) were not significant and were dropped from all
models. In the absence of any significant 3-way interactions,
we examined 2-way interactions (moderator 3 treatment) on
the assumption that treatment differences between levels of the
Table 1 Continued
CBIT
(n 5 124)
PST
(n 5 124)
Antipsychotic and donepezil 0 1 (0.8)
Other 1 (0.8) 0
Abbreviations: CBIT 5 Comprehensive Behavioral Intervention for Tics; PST 5 psychoedu-
cation and supportive therapy.
aGeneralized anxiety, social anxiety, separation anxiety, specific phobia, panic, and post-
traumatic stress disorder.
bMajor depression, substance use disorder, bipolar disorder, eating disorder, and
trichotillomania.
c Haloperidol, pimozide, risperidone, aripiprazole, olanzapine, and fluphenazine.
da-Agonists: guanfacine, clonidine.
e Anticonvulsants: valproate, levetiracetam, topiramate.
f Clonazepam.
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moderator were the same at weeks 5 and 10. To identify
predictors of change on the YGTSS Total Tic score, we
checked for significant main effects for baseline
characteristics regardless of treatment assignment.22 Given
the exploratory nature of these moderator and predictor
analyses, we did not correct for multiple comparisons.26
Dichotomously coded moderator variables were entered in
the mixed model repeated-measures analysis with adjustment
for baseline YGTSS scores. Continuous variables were centered
prior to analysis by subtracting the variable mean from the indi-
vidual scores. Baseline and endpoint adjusted least squares means
and SD for the YGTSS Total Tic score for the CBIT and PST
groups stratified by the moderator variables are presented. Effect
sizes were calculated by subtracting the change in YGTSS scores
in PST from the change in the CBIT divided by the SD for the
full sample at baseline.
RESULTS The combined sample included 177 male
and 71 female participants (n5 248), mean (SD) age
21.5 (613.9) years, range 9–69 years. There were no
significant group differences on any demographic or
clinical variables (table 1). Additional characteristics
of the child and adult participants have been reported
elsewhere.9,10,23,27
Moderation. The presence of tic medication signifi-
cantly moderated response to CBIT, favoring those
on no tic medication (F1,222 5 7.07, p 5 0.01) (fig-
ure). The 4-level tic medication variable (no tic
medication, antipsychotics only, a2 agonists only,
or both) also significantly moderated treatment
response (F3,210 5 3.26, p 5 0.023) (table 2).
Table 3 shows least squares means (LSM) and SD
for participants receiving and not receiving
Figure Moderating effects of tic medication on Yale Global Tic Severity Scale
(YGTSS) Total Tic score
(A) Change from baseline in participants on any tic-suppressing medication (n5 77) to those
not on tic medication. (B, C) Change in YGTSS in participants receiving a2 agonists only (n5
37) and antipsychotic medication only (n5 25). Error bars represent standard errors. CBIT5
Comprehensive Behavioral Intervention for Tics; PST 5 psychoeducation and supportive
therapy.
Table 2 Baseline characteristics examined as
potential moderators of treatment
response (n 5 248)
Category and variable
Test
F p
Concomitant tic medication
Any tic medication (dichotomous variable) 7.07 0.01
Antipsychotics; a-agonists; both; or no
medications (4 groups)
3.26 0.02
Co-occurring disorders
ADHD 0.13 0.72
Severity of ADHD symptoms 0.05 0.95
OCD 0.00 0.98
Any anxiety disordera 1.06 0.30
Tic phenomenology
Age at onset, y 0.04 0.84
Presence of complex tics 1.58 0.21
Tic severity (moderate vs severe on
CGI-S)a
1.36 0.24
Severity of premonitory urgesa 0.68 0.41
Demographic and clinical characteristics
Age (continuous variable) 0.06 0.81
Age (2 groups: 9–15 and 16 and older) 0.11 0.74
Sex 1.51 0.22
Family functioning
Mean family assessment measure score 1.53 0.22
Treatment expectancy
Participant pretreatment expectancya 0.36 0.55
Therapist pretreatment expectancy 0.46 0.50
Abbreviations: ADHD 5 attention-deficit/hyperactivity dis-
order; CGI-S 5 Clinical Global Impression–Severity; OCD 5
obsessive-compulsive disorder.
a Predictors with significant main effect (i.e., baseline
characteristics that predicted change in tics regardless of
treatment that the person has received).
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medication by the treatment condition. Using LSM,
the treatment comparison at week 10 in the CBIT
condition for participants receiving vs not receiving
medication was statistically significant (t5 2.09, p5
0.04). For participants on a2 agonists, the
comparison of week 10 LSM revealed no difference
between CBIT and PST (t 5 0.82, p 5 0.41). In
contrast, participants in the PST condition who were
receiving a2 agonists showed significantly greater tic
reduction that participants not on tic medication (t5
22.37, p 5 0.019).
The presence of ADHD did not moderate treat-
ment effect in participants ,18 years old (n 5 152)
(F1,132 5 0.01, p 5 0.94) or in the combined child
and adult samples (n5 248, F1,2225 0.13, p5 0.72).
Moderating effects of ADHD symptom severity tested
using ADHD-RS z scores were not significant in chil-
dren and adults separately or in the combined sample
(F1,219 5 0.79, p 5 0.38). The presence of OCD or
any anxiety disorder exclusive of OCD did not mod-
erate treatment response (F1,222 5 0.01, p 5 0.1 and
F1,222 5 1.06, p 5 0.30, respectively).
There were no significant treatment interactions
with age at onset, presence of complex tics, tic severity
on the CGI-S, the severity of premonitory urges, sex,
BFAM, participant, or therapist expectancy (table 2).
Baseline age (centered variable), as a continuous vari-
able or when dichotomized into younger and older
age groups, did not moderate outcome.
The effect size for CBIT vs PST was 1.02 for
participants not on tic medication compared to
0.27 for those on tic medication. To evaluate fur-
ther the moderating effects of tic medication, we
compared participants on no tic medication, anti-
psychotics only, a2 agonists only, or both (table 3
and figure). Participants on a2 agonists (CBIT n 5
17; PST n 5 20) showed similar improvement in
both groups (t 5 0.82, p 5 0.41; effect size 5
0.07). By contrast, for participants on antipsychotic
medication (CBIT n 5 14; PST n 5 11), the treat-
ment difference was only slightly lower than the
treatment difference for participants not on tic
medication (t 5 1.39, p 5 0.16; effect size 5
0.77). Table 4 shows the overall rate of positive
response on the CGI-I and by tic medication status.
For participants on no tic medication, the rate of
positive response in CBIT was significantly greater
than for PST. For participants on a tic medication,
the response rate for CBIT was twice that for PST,
but this difference was not significant.
Predictors. There were no significant main effects on
age at onset, presence of complex tics, sex, or family
functioning. Greater overall severity at baseline as
measured on the CGI-S predicted a greater
reduction of tics regardless of treatment condition
(F1,222 5 8.22, p 5 0.005). Greater severity of
premonitory urges at baseline predicted lesser tic
reduction in both treatments (F1,225 5 8.13, p 5
0.005). Positive expectancy by participants was
Table 3 Least squares means (SD) Yale Global Tic Severity Scale Total Tic
scores by treatment group stratified by tic medication, presence of
ADHD, OCD, and anxiety disorders, and by moderate vs severe tics
CBIT PST
Effect sizeBaseline Week 10 Baseline Week 10
Not on tic medication 23.7 (5.9) 16.4 (8.8) 22.5 (6.3) 21.6 (6.1) 1.02
On any tic medication 25.1 (6.9) 18.7 (4.1) 24.5 (6.2) 19.8 (6.2) 0.27
On a2 agonists 26.1 (6.1) 19.6 (5.9) 24.0 (6.0) 17.9 (6.3) 0.07
On antipsychotics 25.6 (7.7) 17.1 (6.5) 24.4 (4.6) 20.8 (6.5) 0.77
No ADHD 24.0 (5.8) 17.1 (6.1) 22.9 (6.0) 21.2 (3.5) 0.83
ADHD 24.4 (7.2) 17.3 (6.1) 23.6 (7.3) 20.5 (11.4) 0.64
No OCD 23.9 (6.2) 17.1 (6.1) 22.8 (6.5) 20.9 (6.2) 0.78
OCD 25.0 (6.5) 17.3 (5.9) 24.4 (5.5) 21.9 (6.1) 0.82
No anxiety 23.8 (6.3) 17.1 (5.9) 23.3 (6.9) 20.5 (6.2) 0.62
Any anxiety diagnosis 25.0 (6.2) 17.4 (6.2) 22.6 (4.7) 22.4 (6.0) 1.17
Moderate ticsa 21.7 (4.9) 16.7 (6.2) 20.9 (5.4) 20.1 (6.1) 0.93
Marked/severe ticsa 28.9 (5.9) 18.0 (6.1) 26.8 (6.0) 23.0 (6.4) 1.18
Abbreviations: ADHD 5 attention-deficit/hyperactivity disorder; CBIT 5 Comprehensive
Behavioral Intervention for Tics; OCD 5 obsessive-compulsive disorder; PST 5 psychoedu-
cation and supportive therapy.
a As measured on Clinical Global Impression–Severity.
Table 4 Rates of positive response on Clinical Global Impression–Improvement
scale by tic medication status in combined sample (n 5 248)
Positive
response, n (%)
Negative
response, n (%) Test, p value
Unadjusted
odds ratio
Overall
CBIT 56 (45.2) 68 (54.8)
PST 16 (12.9) 108 (87.1) x2 5 29.77, p , 0.0001 5.56
Not on tic
medication
CBIT 43 (51.2) 41 (48.8)
PST 10 (11.5) 77 (88.5) x2 5 31.49, p , 0.0001 8.07
On any tic
medication
CBIT 13 (32.5) 27 (67.5)
PST 6 (16.2) 31 (83.8) x2 5 2.74, p 5 0.098 2.49
On a2 agonists
CBIT 8 (47.1) 9 (52.9)
PST 5 (25.0) 15 (75.0) Fisher exact, p 5 0.188 2.66
On
antipsychotics
CBIT 3 (21.4) 11 (78.6)
PST 1 (9.1) 10 (90.9) Fisher exact, p 5 0.604 2.73
Abbreviations: CBIT 5 Comprehensive Behavioral Intervention for Tics; PST 5 psychoedu-
cation and supportive therapy.
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a significant predictor of treatment benefit (F1,210 5
6.72, p 5 0.01). Anxiety disorders (exclusive of
OCD) predicted lower tic reduction at week 10
regardless of treatment condition (F1,222 5 4.17,
p 5 0.042). Otherwise co-occurring psychiatric
disorders did not predict treatment outcome.
DISCUSSION Data from the child and adult CBIT vs
PST trials (n 5 248) were combined to examine
moderators and predictors of treatment response.
Compared to participants on tic medication, the
treatment effect of CBIT was significantly larger in
participants on no tic medication. This differential
response was evident in the YGTSS Total Tic score
and the rate of positive response on the CGI-I scored
by a blinded evaluator. The presence of a lifetime
diagnosis of ADHD, OCD, or other anxiety
disorders did not moderate treatment response to
CBIT, nor did age, sex, current severity of ADHD
symptoms, tic severity, or severity of premonitory
urges.
The moderating effect of tic-suppressing medica-
tion warrants closer inspection. First, the use of
tic-suppressing medication may indicate greater tic
severity. At baseline, there was no difference in
YGTSS Total Tic scores in participants on tic medi-
cation compared to those not taking a tic medication.
However, because the premedication tic severity for
those on tic medication is unknown, the role of tic
severity in these analyses is unclear.
Second, of the 248 participants, only 77 (31%)
were on a tic-suppressing medication (primarily anti-
psychotics or a2 agonists). As shown in table 3, the
difference in YGTSS change scores between CBIT
and PST was 1.7 points for participants on any tic
medication compared to a difference of 6.4 points for
participants not on tic medication (effect sizes 0.27
and 1.02, respectively). Although the numbers are
small, there were differences by drug class. The
CBIT-PST YGTSS change-score difference for par-
ticipants on antipsychotic medications was 4.9 points
(effect size 0.77), which was similar to the improve-
ment in participants on no tic medication. By con-
trast, for participants on a2 agonists, the difference in
YGTSS change scores between treatments was 0.4
points (effect size 0.07). This attenuated effect size
was largely due to the 6.1-point improvement in the
YGTSS in the PST group on a2 agonists compared
to a 6.5-point reduction in CBIT. When examined
categorically on the CGI-I, participants on no tic
medication showed a higher positive response rate
than those on tic medication with no apparent differ-
ence by drug class.
Although participants not on tic medication
showed greater magnitude of benefit and likelihood
of positive response, participants on tic medication
also showed improvement with CBIT. Thus, within
the CBIT group, there was a 7.3-point reduction in
the YGTSS Total Tic score in participants not on
tic-suppressing medication. This is remarkably
similar to the 6.5-point reduction for CBIT in partic-
ipants receiving a2 agonists for tics and the 8.5-point
reduction in participants on antipsychotics for tics.
The 6.1-point decrease in tic severity in the PST
group on a2 agonists for tics reduced the treatment
difference between CBIT and PST for all participants
on tic medication and may explain the significant
interaction. The smaller CBIT-PST treatment differ-
ence in participants on a2 agonists need not imply
that patients on a2 agonists should not be offered
CBIT.
The predictor analysis identified 4 variables that
affected outcome regardless of treatment assignment:
co-occurring anxiety disorders, severity of premoni-
tory urges, participant positive expectancy, and higher
overall severity as measured on the CGI-S. Partici-
pants with a co-occurring anxiety disorder showed
less tic reduction after 10 weeks. Although CBIT in-
cludes brief relaxation training, incorporation of more
active anxiety and stress management strategies in
CBIT may be useful. The severity of premonitory
urges was also associated with lower tic reduction.
Despite the deliberate teaching on early detection of
the urge and initiation of voluntary competing
response in CBIT, premonitory urges did not
improve with CBIT.9,10 The current analysis suggests
that the severity of premonitory urges impeded
improvement in both study treatments. Greater levels
of premonitory urges may be associated with more
treatment-resistant forms of CTDs.28
Positive expectancy for change among study par-
ticipants and parents was associated with greater tic
reduction over time. This nonspecific effect suggests
that some participants and their parents were optimis-
tic that therapeutic attention to the problem of
chronic tics could be beneficial.29 When overall sever-
ity was dichotomized on CGI-S of moderate vs
marked or greater, participants with greater overall
severity also showed greater tic reduction over time
regardless of treatment condition.
Positive expectations for treatment depend, at least
in part, on agreement between the patient and the cli-
nician on the goals of treatment as well as the specific
components of the therapy.30 Thus, open discussion
about the goal (tic reduction) and techniques of
CBIT (e.g., awareness training and competing
response training) between the therapist and the
patient is warranted.
These results should be considered in light of lim-
itations. First, the CBIT studies were designed to test
main effects. By definition, moderator and predictor
analyses are exploratory. Second, although the effect
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size and likelihood of positive response were lower for
participants on tic medication, the subgroups by
medication class were small, making it difficult to
interpret the findings.
CBIT is helpful for reducing tics in children and
adults regardless of coexisting tic medication treat-
ment, although the difference between CBIT and
PST was smaller for participants on tic-suppressing
medications. PST was designed to include psycho-
education and support that are part of good clinical
practice and it should be provided to patients in con-
junction with medication management for tics. The
presence of common co-occurring conditions in chil-
dren and adults with CTDs did not moderate treat-
ment effects, suggesting that CBIT is effective for
reducing tic severity in patients with stable co-
occurring conditions.
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